Tag
The MINT trial reveals that liberal transfusion strategies in MI patients with anemia, including those with heart failure, reduce adverse outcomes compared to restrictive transfusion, supporting a tailored approach to transfusion management
The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.
Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac impla
This study analyses maternal and neonatal outcomes in subsequent pregnancies after peri-partum cardiomyopathy (PPCM), revealing lower than expected maternal risks and suggesting potential reclassification of pregnancy risk categories based
Linea integrates generative AI and high-touch virtual nursing to proactively manage heart failure patients, achieving a 50% reduction in hospital readmissions within 90 days, substantially lowering costs and improving patient outcomes.
In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.
The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients wit
Acute tetrahydrobiopterin (BH4) administration improves locomotor muscle microvascular function in heart failure patients, highlighting the nitric oxide pathway as a promising therapeutic target, while acute antioxidant therapy showed no be
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati
This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over o
The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.
This study evaluates the risk of ischaemic and non-ischaemic heart failure in over 1.6 million individuals with type 2 diabetes, highlighting critical insights for prevention strategies.
New data show an increased risk of heart failure among elderly Medicare patients initiating pregabalin versus gabapentin for chronic noncancer pain, particularly in those with cardiovascular disease history.
